Acute Telogen Effluvium Related To COVID-19 Infection: A Review
DOI:
https://doi.org/10.66344/jpad.v32i3.1913Abstract
Background Since being declared a pandemic, Coronavirus Disease 19 (COVID-19) has spread worldwide and causes various manifestations, including hair symptoms. Infection with COVID-19 produces inflammation and stress, which results in dermatological symptoms affecting the skin and hair. The most common hair loss-related finding in COVID-19 instances is Telogen Effluvium (TE), which is characterized by widespread non-scarring hair loss. The hair shedding that occurs usually happens two to three months after infection. In this article, we review and summarize how hair loss was induced in COVID-19 infections, how TE and COVID-19 severity is associated, as well as the duration and onset of TE following COVID-19 infections.
Methods A literature search through PubMed was performed and nine studies were found. Studies included case reports and case series published from 2020 to 2021.
Results From the nine studies reviewed, we found more than 50% of females suffered from post-COVID TE, with an age range of 20-76 years old and a mean age of 42.89 years old. The average number of days to TE onset was ±63 days after COVID-19 infection. TE was discovered in patients with mild to moderate COVID-19. Several studies have found that Caucasians are more likely to suffer from TE compared to other racial groups. The comorbidities in most of the patients included vitamin D deficiency, anemia, hypothyroidism, and type 2 diabetes mellitus.
Conclusion Various factors influence post-COVID TE, including age, time of onset, gender, severity of COVID-19 infection, and pre-existing comorbidities (vitamin D deficiency, anemia, hypothyroidism, and type 2 diabetes mellitus).
References
1. Ohyama M. Telogen Effluvium. In: Kang S, Masayuki A, Anna L.B et al., editors. Fitzpatrick's Dermatology in General Medicine. 9th edn. New York: McGraw-Hill; 2019. p.989.
2. Rizzetto G, Diotallevi F, Campanati A, et al. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. 2021;34(1):e14547.
3. Sharquie KE, Jabbar RI. COVID-19 infection is a major cause of acute telogen effluvium. Ir J Med Sci. 2021;1-5.
4. Mohseni Afshar Z, Babazadeh A, Hasanpour A, et al. Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge. J Med Virol. 2021;93(10):5756-67.
5. Olds H, Liu J, Luk K, et al. Telogen effluvium associated with COVID-19 infection. Dermatol Ther. 2021; 34(2):e14761.
6. Maymone MBC, Laughter M, Pollock S, et al. Hair Aging in Different Races and Ethnicities. J Clin Aesthet Dermatol. 2021;14(1):38-44.
7. Babaei K, Kavoussi H, Rezaei M, et al. Characteristics of telogen effluvium in COVID-19 in western Iran (2020). An Bras Dermatol. 2021;96(6):688-92.
8. Saeed W, Hussain I, Altaf F. Telogen effluvium : Long term Covid-19 Symptom. J Pak Assoc Dermatol. 2020;30(4): 695-8.
9. Wei N, Elbogen E, Dan J, et al. Telogen Effluvium in Patients Recovering from COVID-19. SKIN The Journal of Cutaneous Medicine. 2021;5(5):533–7.
10. Asghar F, Shamim N, Farooque U, et al. Telogen Effluvium: A Review of the Literature. Cureus. 2020;12(5):e8320.
11. Alotaibi, M. Telogen Effluvium. J Turk Acad Dermatol. 2018;12(4):18124r1.
12. Del Valle D.M, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–43.
13. Rossi A, Magri F, Sernicola A, et al. Telogen Effluvium after SARS-CoV-2 Infection: A Series of Cases and Possible Pathogenetic Mechanisms. Skin Appendage Disord. 2021;21(5):1-5.
14. Rivetti N, Barruscotti S. Management of telogen effluvium during the COVID-19 emergency: Psychological implications. Dermatol Ther. 2020;33(4):e13648.
15. Fatani M.I, Bin Mahfoz A.M, Mahdi A.H, et al. Prevalence and factors associated with telogen effluvium in adult females at Makkah region, Saudi Arabia: A retrospective study. J Dermatol Surg. 2015;19(1);27–30
16. Grymowicz M, Rudnicka E, Podfigurna A, et al. Hormonal Effects on Hair Follicles. Int J Mol Sci. 2020;21(15):5342.
17. Ozuguz P, Kacar SD, Ekiz O, et al. Evaluation of Zinc, Vitamin B12, Folic Acid and Iron Levels and Thyroid Functions in Patients with Chronic Telogen Effluvium. J Dermatol Res Ther. 2015;1(1):008.
18. Kakpovbia E, Ogbechie-Godec OA, Shapiro J, et al. Laboratory Testing in Telogen Effluvium. J Drugs Dermatol. 2021;20(1):110-1.
19. Demay MB, MacDonald PN, Skorija K, et al. Role of the vitamin D receptor in hair follicle biology. J Steroid Biochem Mol Biol. 2007;103(3-5):344-6.
20. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatol Ther (Heidelb). 2019;9(1):51-70.
21. Grover C, Khurana A. Telogen effluvium. Indian J Dermatol Venereol Leprol. 2013;79(5):591-603.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 July Iriani Rahardja, Anna Rumaisyah, Desica Natalisa Simanjuntak, Geby Khomaro Putri
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
